Skip to main content
Evidence Snapshot

Lanosterol 14-alpha demethylase

CHEMBL3849 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:24:37Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3849
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Lanosterol 14-alpha demethylase as ChEMBL target CHEMBL3849, mapped to UniProt Q16850. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Lanosterol 14-alpha demethylase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3849
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q16850
Lanosterol 14-alpha demethylase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Lanosterol 14-alpha demethylase matters

As of 2026-09-13

Lanosterol 14-alpha demethylase is reviewed as Lanosterol 14-alpha demethylase (UniProt Q16850); the current evidence base includes 12 approved drugs, 87 compounds, and 21 assays, with lead potency reaching pChEMBL 7.8.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 12 approved drugs, 87 compounds, and 21 assays for this target. The dominant activity type is IC50. CHEMBL305220 is the current potency anchor at pChEMBL 7.8.

Use CHEMBL305220 as the tractability anchor when discussing potency (pChEMBL 7.8).

Activity source · ChEMBL 36 via Core Engine
12 approved pChEMBL 7.8
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Lanosterol 14-alpha demethylase matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q16850, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

87
Total Compounds
21
Total Assays
12
Approved Drugs
IC50: 84.0, KI: 4.0, KD: 30.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL305220
 7.8 Ki —
No preferred name
CHEMBL4461447
 7.7 Kd —
No preferred name
CHEMBL157101
 7.6 Ki Approved
No preferred name
CHEMBL808
 7.3 IC50 Approved
No preferred name
CHEMBL4277680
 7.2 Kd —

Approved Drugs

Structure Compound First Approval
ECONAZOLE
CHEMBL808
 1982
KETOCONAZOLE
CHEMBL157101
 1981
CLOTRIMAZOLE
CHEMBL104
 1975
MICONAZOLE
CHEMBL91
 1974
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:24:37Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3849